1. Beta-Blockers and Fetal Growth Restriction in Pregnant Women With Cardiovascular Disease
- Author
-
Masami Sawada, Tomoaki Ikeda, Naoko Iwanaga, Kayo Tanaka, Chizuko Kamiya, Hiroaki Tanaka, Jun Yoshimatsu, Mitsuhiro Tsuritani, Shinji Katsuragi, and Masashi Yoshida
- Subjects
Adult ,medicine.medical_specialty ,Adrenergic beta-Antagonists ,Pregnancy Complications, Cardiovascular ,Propranolol ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,Pregnancy ,Risk Factors ,Internal medicine ,medicine ,Humans ,030212 general & internal medicine ,Carvedilol ,Retrospective Studies ,Metoprolol ,Fetal Growth Retardation ,Beta-adrenergic blocking agent ,business.industry ,Incidence (epidemiology) ,General Medicine ,Atenolol ,medicine.disease ,Endocrinology ,Bisoprolol ,Female ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
BACKGROUND The effects of β-adrenergic blockers on the fetus are not well understood. We analyzed the maternal and neonatal outcomes of β-adrenergic blocker treatment during pregnancy to identify the risk of fetal growth restriction (FGR). METHODS AND RESULTS We retrospectively reviewed 158 pregnancies in women with cardiovascular disease at a single center. Maternal and neonatal outcomes were analyzed in 3 categories: the carvedilol (α/β-adrenergic blocker; α/β group, n=13); β-adrenergic blocker (β group, n=45), and control groups (n=100). Maternal outcome was not significantly different between the groups. FGR occurred in 1 patient (7%) in the α/β group, in 12 (26%) in the β group, and in 3 (3%) in the control group; there was a significant difference between the incidence of FGR between the β group and control group (P
- Published
- 2016
- Full Text
- View/download PDF